TransEnterix Announces Kitakyushu General Hospital in Japan to Initiate a Senhance Digital Laparoscopy Program
January 29 2020 - 4:05PM
Business Wire
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that the Kitakyushu General Hospital, a hospital in southwestern
Japan, has entered into an agreement to lease and utilize a
Senhance® System.
“We are excited to partner with Kitakyushu General Hospital to
build its Senhance Digital Laparoscopy Program,” said Anthony
Fernando, president and chief executive officer at TransEnterix.
“We believe the Senhance System, with its digital laparoscopic
interface and responsible economics, is a great fit for the
Japanese market. With our first system at Saitama Medical
University and now a second system with Kitakyushu General
Hospital, we are building the foundation for future Senhance
success in Japan.”
Kitakyushu General Hospital is a prestigious institution and is
recognized as one of the major hospitals in Kitakyushu. It offers
both advanced and emergency medical care and is a core part of the
Kitakyushu Hospital Group. It is a 360-bed facility that contains a
critical care center and is the only general hospital in the
Kitakyushu Hospital Group.
“Improving patient care through innovative technologies is
important to our hospital,” said Dr. Naoki Nagata, President of
Kitakyushu General Hospital. “Senhance will be a welcome addition
to our minimally invasive surgery program, leveraging our existing
laparoscopic skill sets, enabling maximum precision, visualization
and control during delicate surgeries and doing so with
cost-effective technology, which addresses the need to minimize
healthcare costs.”
The Senhance® Surgical System is the first and only digital
laparoscopic platform designed to maintain laparoscopic MIS
standards while providing digital benefits such as haptic feedback,
robotic precision, eye-sensing camera control, comfortable
ergonomics, advanced instrumentation including, 3 mm
microlaparoscopic instruments, eye-sensing camera control and
reusable standard instruments to help maintaining per-procedure
costs similar to traditional laparoscopy.
The Senhance Surgical System was approved for use by the
Japanese Ministry of Health, Labor and Welfare (MHLW) in 2019, and
has the broadest procedural reimbursement of any abdominal robotic
surgery platform in Japan, which applies to 98 benign and malignant
laparoscopic procedures across general, colorectal, gynecologic,
pediatric and urologic surgeries at reimbursement rates equivalent
to traditional laparoscopy in Category A1.
Japan is the second-largest medical device market in the world,
valued at over $40 billion annually, including over $5 billion in
capital equipment spending. There are more than 8,400 hospitals in
Japan, of which approximately 80% are private entities. Japanese
laparoscopic penetration in surgery is among the highest in the
world. The central government has implemented cost containment
initiatives in recent years and has approached recent procedure
approvals for robotics by establishing reimbursement at the same
rate as traditional laparoscopy, which places a high emphasis on
procedure cost to influence adoption.
About TransEnterix
TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
commercialization of the Senhance Surgical System, which digitizes
laparoscopic minimally invasive surgery. The system allows for
robotic precision, haptic feedback, surgeon camera control via eye
sensing and improved ergonomics while offering responsible
economics. The Senhance Surgical System is available for sale in
the US, the EU, Japan and select other countries. For more
information, visit www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and the Kitakyushu General Hospital initiating a program
with the Senhance System. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether the Senhance System, with its digital laparoscopic
interface and responsible economics, will be a great fit for the
Japanese market, and whether the placement of a Senhance System
with Kitakyushu General Hospital, following a placement at Saitama
Medical University, will build a foundation for future Senhance
success in Japan. For a discussion of the risks and uncertainties
associated with TransEnterix's business, please review our filings
with the Securities and Exchange Commission (SEC), including our
Annual Report on Form 10-K for the year ended December 31, 2018,
filed with the SEC on February 27, 2019 and our other filings we
make with the SEC. You are cautioned not to place undue reliance on
these forward looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the origination date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200129005659/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com or Media Contact: Terri
Clevenger, +1 203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Apr 2023 to Apr 2024